Tangled Labs Oy

Tangled Labs Oy, based in Finland, specializes in developing innovative social coding platforms that enhance collaborative software development while ensuring code ownership for developers. Founded in 2025 by co-founders Akshay and Anirudh Oppiliappan, Tangled Labs Oy operates from Helsinki, Finland, and is focused on creating a platform that promotes collaborative coding. In March 2026, Tangled Labs Oy raised EUR 3. 8 million in seed funding led by investor byFounders, with participation from another investor Bain Capital Crypto and Antler.

Tangled offers a next-generation social coding platform designed to foster collaborative development while ensuring that developers maintain ownership of their code. The platform features a novel approach to pull requests, allowing users to break down large features into manageable, reviewable chunks, and stack pull requests to streamline the code review process. Tangled integrates with Jujutsu to support pull request stacking natively, enhancing the efficiency of development workflows. The platform is versatile, allowing users to host repositories on their own infrastructure using "knots" and run continuous integration (CI) processes on local machines through "spindles.

" For those who prefer not to self-host, Tangled provides hosted instances accessible to a broad audience, serving developers and coding communities globally, particularly in regions with strong tech startup presence. Tangled's revenue model is primarily based on subscription services, enabling clients to access their social coding platform and associated tools. Clients subscribe to utilize features such as repository hosting and CI services. The structure likely includes tiered subscription options catering to the varying needs of individual users, small teams, and larger organizations, alongside potential partnerships for enhanced functionalities and integrations.

Key offerings include repository hosting services and innovative pull request management tools. The company will use the March 2026 funding to scale training of its pathology foundation model, expand its team, and support early clinical and pharmaceutical collaborations.